Stock Screener App

Frei -

Installieren

171.61

3.85% -6.88

after-market

Handel nachbörslich: 171.80 0.19 +0.11%

Astrazeneca Plc (AZN)

Überblick Nachrichten Preisverlauf Optionskette Warum fällt AZN? Forum Prognose Aktiensplit Dividendenhistorie

Astrazeneca Plc Aktie (AZN) Neueste Nachrichten

Why Did AstraZeneca (AZN) Stock Dip More Than the Market Today - Kavout | AI

Astrazeneca (AZN) Stock Dips While Market Gains: Key Facts - Yahoo Finance

AstraZeneca's $27 Billion TTR Wipeout Hands Alnylam the Market — But Its Own Trial Has the Same Flaw - finance.biggo.com

AstraZeneca's (AZN) Vaccine Influence Under Scrutiny Amid New Ad - GuruFocus

AstraZeneca Selloff Looks Larger Than the Wainua Valuation Damage - Investing.com

AstraZeneca’s Embold Trial Signals a Big Push Into the Obesity Drug Race - TipRanks

Ionis, AstraZeneca Stumble in ATTR-CM Trial as Rivals Stand to Gain - Benzinga

AstraZeneca PLC Stock (AZN) Moved Down by 3.50% on Jul 10: Key Drivers Unveiled - TradingKey

AZN slides over 3% as Wainua Phase III clinical trial fails to meet efficacy goals - Traders Union

ASTRAZENECA : Deutsche Bank reaffirms its Sell rating - marketscreener.com

AstraZeneca: An unexpected late-stage failure doesn't derail Astra - marketscreener.com

AstraZeneca Stock Tumbles 6% Following Late-Stage Heart Disease Drug Trial Failure - TIKR.com

ASTRAZENECA : Bernstein keeps its Buy rating - marketscreener.com

AstraZeneca Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into AstraZeneca (AZN) - PR Newswire

Sino and AstraZeneca sign licence agreement for TQC3721 - Pharmaceutical Technology

AstraZeneca PLC (AZN) Shares Fall 5.7% -- What GF Score of 82 Te - GuruFocus

Fed. Circ. Affirms AstraZeneca Win Over $107.5M Verdict - Law360

AstraZeneca (AZN) Wins Patent Dispute Over Tagrisso - GuruFocus

AstraZeneca wins appeal in Pfizer patent dispute over Tagrisso By Investing.com - Investing.com Nigeria

AstraZeneca Extends Anifrolumab Access With New ROSY-S Rollover Study - TipRanks

FTSE 100 held back by AstraZeneca trial setback - Yahoo Finance UK

UK's FTSE 100 ticks lower as AstraZeneca drag offsets banks, mining gains - marketscreener.com

AstraZeneca slips Thursday, underperforms market - MarketWatch

Micron Surges on AI Chip Report, Meta and AstraZeneca Dip - StartupHub.ai

AstraZeneca and Ionis’ stocks drop significantly on Wainua ATTR-CM trial failure - Clinical Trials Arena

UK Stocks Drop as AstraZeneca's Heart Drug Trial Results, Geopolitical Tensions Weigh - marketscreener.com

AstraZeneca shares dive on rare trial failure of heart drug - The Malaysian Reserve

AstraZeneca PLC Stock (AZN) Moved Down by 6.72% on Jul 9: A Full Analysis - TradingKey

AstraZeneca's Stock Drops on Wainua's Setback in ATTR-CM Study - Yahoo Finance

AstraZeneca Shares Dive on Rare Trial Failure of Heart Drug - Bloomberg.com

ASTRAZENECA : Jefferies keeps its Buy rating - marketscreener.com

AstraZeneca, Ionis Shares Slide After Wainua Misses Target in Heart Disease Trial - WSJ

AstraZeneca's Wainua failure hurts credibility more than valuation, Jefferies warns - Proactive Investors

AstraZeneca stock holds steady on its global pipeline - Ad-hoc-news.de

ASTRAZENECA : Bernstein remains its Buy rating - marketscreener.com

AstraZeneca (AZN) Stock Plunges 9% as Wainua Trial Misses Primary Endpoint - Blockonomi

Breakfast News: AstraZeneca's Heart Drug Flatlines - The Motley Fool

AstraZeneca, Ionis drug fails big heart disease study in major setback - BioPharma Dive

Why Is Ionis Pharmaceuticals, AstraZeneca Stock Tumbling Today?AstraZeneca (NYSE:AZN), Ionis Pharmaceu - Benzinga

AstraZeneca Cardiomyopathy Drug Wainua Fails to Meet Late-Stage Clinical Trial Goal as Shares Plunge Over 8% Pre-Market. - TradingKey

AstraZeneca stock drops 9% after Wainua heart drug trial fails - Yahoo Finance

London's FTSE 100 slips as Middle East tensions persist, AstraZeneca drags - marketscreener.com

AstraZeneca licenses Sino's COPD drug for $2.1bn - BioXconomy

ASTRAZENECA : Buy rating from Goldman Sachs - marketscreener.com

AstraZeneca sees stock market value slump by more than £20bn after drug setback - Yahoo Finance UK

AstraZeneca plc focuses on long-term growth. Oncology and vaccines underpin its strategy - Ad-hoc-news.de

Wainua heart trial misses primary endpoint for AstraZeneca (NYSE: AZN) - Stock Titan

ASTRAZENECA : Buy rating from Jefferies - marketscreener.com

ASTRAZENECA : JP Morgan reiterates its Buy rating - marketscreener.com

AstraZeneca (AZN) Shares Plunge Following Trial Setback - GuruFocus

AstraZeneca Shares Slide After Heart Drug Trial Misses Primary Endpoint - Yahoo Finance UK

Ionis, AstraZeneca Report Amyloid Cardiomyopathy Treatment Failed to Meet Primary Endpoint in Phase 3 - marketscreener.com

AstraZeneca shares slump after clinical trial fails - marketscreener.com

FTSE 100 lags Europe as AstraZeneca sinks - marketscreener.com

AstraZeneca's Baxfendy Set For Blockbuster Sales After Hypertension Approval - Seeking Alpha

AstraZeneca shares fall 9% as cardiovascular drug Wainua fails test - marketscreener.com

AstraZeneca's £19bn blow as Wainua heart drug fails key late-stage trial - Proactive financial news

AstraZeneca tumbles as heart drug trial misses main efficacy goal (AZN:NYSE) - Seeking Alpha

AstraZeneca tumbles, Schott Pharma raises its ambitions - marketscreener.com

The failure of a clinical trial sends AstraZeneca shares tumbling - marketscreener.com

AstraZeneca drops 9% on disappointing heart trial - Breakingthenews.net

AstraZeneca shares slide after heart treatment disappoints in trial - Financial Times

AstraZeneca’s Wainua Falls Short in Phase III ATTR-CM Study Despite Positive Subgroup Signal (AVG) - Yahoo Finance UK

AstraZeneca And Ionis’ Wainua Misses Phase III ATTR-CM Trial Endpoint - DirectorsTalk Interviews

REGAstraZeneca PLCUpdate on CARDIO-TTRansform Phase III trial - TradingView

AstraZeneca Employee Traded On Icosavax Deal, SEC Says - Law360

Watch AstraZeneca Drug Trial Failure Sends Shares Plunging - Bloomberg.com

AstraZeneca (AZN) Receives FDA Orphan Designation for Kidney Dis - GuruFocus

AstraZeneca (AZN) officer receives share grant via incentive plan - Stock Titan

Astrazeneca nabs PDE3/4 inhibitor for COPD in $2.1B Sino deal - BioWorld News

NVS

$154.05

0.37%

MRK

$123.54

1.22%

NVO

$49.48

1.23%

AMGN

$363.39

0.06%

GILD

$129.83

3.72%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters